Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer

• Published in: Oncology letters Vol. 4; no. 6; pp. 1309 - 1314
• Main Authors: XUE, SHENG-LIU, SU, HUA-FANG, HU, XIAO-QU, DENG, XIA, HU, MEI-LONG, XIE, CONG-YING
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.12.2012; Spandidos Publications UK Ltd
• Subjects: Abdomen; adjuvant chemotherapy; Biomarkers; Blood; Cancer therapies; Chemotherapy; combined therapy; Family medical history; Gastric cancer; Hematology; intraperitoneal chemotherapy; locally advanced gastric cancer; Medical imaging; Metastasis; Mortality; Oncology; Studies; Surgery; Surgical outcomes; China
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2012.914

The optimal adjuvant treatment modality for gastric cancer has not been well defined. The aim of this study was to evaluate the efficacy and feasibility of adjuvant combined systemic and intraperitoneal chemotherapy (ACSIP) in high-risk patients with locally advanced gastric cancer. Between June 2003 and December 2008, 62 eligible patients with serosa-infiltrating and/or node-positive gastric cancer following curative gastrectomy with D2 lymphadenectomy received ACSIP, consisting of intravenous oxaliplatin 85 mg/m2 on day 1 followed by leucovorin (LV) 200 mg/m2 and 5-fluorouracil (5-FU) 450 mg/m2 on days 1-3, intraperitoneal 5-FU 600 mg/m2 on days 4-5 and cisplatin (CDDP) 40 mg/m2 on day 5. Survival rates, the sites of first treatment failure and safety were analyzed. At a median follow-up of 45 months (range 7-101), the 3-year disease-free survival (DFS) and overall survival (OS) rates were 66.1 and 74.2%, respectively. Initial peritoneal and hepatic failures were found in 6 (24.0%) and 3 (12.0%) of the 25 patients with recurrence, respectively. Neutropenia, gastrointestinal side effects and peripheral neuropathy were the most common grade 3-4 toxicities; however, they were all infrequent and manageable. No serious surgical complications or treatment-related mortality was observed. The results of this study indicate that ACSIP is effective and feasible for locally advanced gastric cancer with encouraging survival rates and possibly decreased peritoneal and hepatic recurrences. The benefits of this promising combined adjuvant treatment modality warrant further studies.